We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
So far, there are four HCV DAAs marketed in Mainland China, including the above two, BMS’ Asunaprevir soft capsule and Daclatasvir Dihydrochloride Tables combined therapy, and J & J’s Simeprevir.